Gland Pharma Statistics
Total Valuation
Gland Pharma has a market cap or net worth of INR 278.39 billion. The enterprise value is 251.03 billion.
Market Cap | 278.39B |
Enterprise Value | 251.03B |
Important Dates
The last earnings date was Tuesday, May 20, 2025.
Earnings Date | May 20, 2025 |
Ex-Dividend Date | Aug 14, 2025 |
Share Statistics
Gland Pharma has 164.76 million shares outstanding. The number of shares has increased by 0.01% in one year.
Current Share Class | 164.76M |
Shares Outstanding | 164.76M |
Shares Change (YoY) | +0.01% |
Shares Change (QoQ) | -0.01% |
Owned by Insiders (%) | 0.01% |
Owned by Institutions (%) | 37.36% |
Float | 73.18M |
Valuation Ratios
The trailing PE ratio is 39.85 and the forward PE ratio is 29.56. Gland Pharma's PEG ratio is 1.37.
PE Ratio | 39.85 |
Forward PE | 29.56 |
PS Ratio | 4.96 |
PB Ratio | 3.04 |
P/TBV Ratio | 3.16 |
P/FCF Ratio | 52.51 |
P/OCF Ratio | 30.43 |
PEG Ratio | 1.37 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.78, with an EV/FCF ratio of 47.35.
EV / Earnings | 35.94 |
EV / Sales | 4.47 |
EV / EBITDA | 19.78 |
EV / EBIT | 28.17 |
EV / FCF | 47.35 |
Financial Position
The company has a current ratio of 4.33, with a Debt / Equity ratio of 0.03.
Current Ratio | 4.33 |
Quick Ratio | 2.92 |
Debt / Equity | 0.03 |
Debt / EBITDA | 0.25 |
Debt / FCF | 0.59 |
Interest Coverage | 21.22 |
Financial Efficiency
Return on equity (ROE) is 7.82% and return on invested capital (ROIC) is 6.00%.
Return on Equity (ROE) | 7.82% |
Return on Assets (ROA) | 5.09% |
Return on Invested Capital (ROIC) | 6.00% |
Return on Capital Employed (ROCE) | 9.22% |
Revenue Per Employee | 13.10M |
Profits Per Employee | 1.63M |
Employee Count | 4,286 |
Asset Turnover | 0.51 |
Inventory Turnover | 1.36 |
Taxes
In the past 12 months, Gland Pharma has paid 3.64 billion in taxes.
Income Tax | 3.64B |
Effective Tax Rate | 34.27% |
Stock Price Statistics
The stock price has decreased by -9.82% in the last 52 weeks. The beta is 0.32, so Gland Pharma's price volatility has been lower than the market average.
Beta (5Y) | 0.32 |
52-Week Price Change | -9.82% |
50-Day Moving Average | 1,503.42 |
200-Day Moving Average | 1,651.81 |
Relative Strength Index (RSI) | 74.87 |
Average Volume (20 Days) | 168,749 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gland Pharma had revenue of INR 56.17 billion and earned 6.99 billion in profits. Earnings per share was 42.40.
Revenue | 56.17B |
Gross Profit | 33.27B |
Operating Income | 8.91B |
Pretax Income | 10.63B |
Net Income | 6.99B |
EBITDA | 12.69B |
EBIT | 8.91B |
Earnings Per Share (EPS) | 42.40 |
Balance Sheet
The company has 30.50 billion in cash and 3.14 billion in debt, giving a net cash position of 27.36 billion or 166.07 per share.
Cash & Cash Equivalents | 30.50B |
Total Debt | 3.14B |
Net Cash | 27.36B |
Net Cash Per Share | 166.07 |
Equity (Book Value) | 91.51B |
Book Value Per Share | 555.30 |
Working Capital | 52.18B |
Cash Flow
In the last 12 months, operating cash flow was 9.15 billion and capital expenditures -3.85 billion, giving a free cash flow of 5.30 billion.
Operating Cash Flow | 9.15B |
Capital Expenditures | -3.85B |
Free Cash Flow | 5.30B |
FCF Per Share | 32.18 |
Margins
Gross margin is 59.24%, with operating and profit margins of 15.86% and 12.44%.
Gross Margin | 59.24% |
Operating Margin | 15.86% |
Pretax Margin | 18.92% |
Profit Margin | 12.44% |
EBITDA Margin | 22.59% |
EBIT Margin | 15.86% |
FCF Margin | 9.44% |
Dividends & Yields
This stock pays an annual dividend of 18.00, which amounts to a dividend yield of 1.07%.
Dividend Per Share | 18.00 |
Dividend Yield | 1.07% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | 1 |
Payout Ratio | 47.17% |
Buyback Yield | -0.01% |
Shareholder Yield | 1.06% |
Earnings Yield | 2.51% |
FCF Yield | 1.90% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | |
Lynch Upside | |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 7 |